The British journal of dermatology

The most recent articles from: Br. J. Dermatol. October 2017

Br. J. Dermatol. · Oct 2017

Randomized Controlled Trial Multicenter Study Comparative Study

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

It has been shown that the interleukin (IL)-23/IL-17 axis is critical in the pathogenesis of psoriasis. ⋯ The superior efficacy of IXE demonstrated at week 12 persisted up to week 24. The safety profiles were consistent with those previously reported for both treatments.

read on… or not…
Br. J. Dermatol. · Oct 2017

Randomized Controlled Trial Multicenter Study Comparative Study

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.

Secukinumab is a fully human antibody that neutralizes interleukin-17A. It has significant efficacy and a favourable safety profile in moderate-to-severe plaque psoriasis and psoriatic arthritis. ⋯ Secukinumab demonstrated superior efficacy to FAEs in patients with psoriasis over a 24-week period.

read more… mark as read…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!